There are 2789 resources available
699P - Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
Presenter: Jonathan Rosenberg
Session: ePoster Display
700P - Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)
Presenter: Yohann Loriot
Session: ePoster Display
591P - A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC)
Presenter: Rahul Aggarwal
Session: ePoster Display
592P - Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Michael Schweizer
Session: ePoster Display
593P - Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Celestia Higano
Session: ePoster Display
594P - Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
Presenter: Holger Palmedo
Session: ePoster Display
641TiP - Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H
Presenter: Johann de Bono
Session: ePoster Display
642TiP - Phase II CA184-585 (INSPIRE) trial of ipilimumab with nivolumab for molecular-selected patients with castration-resistant prostate cancer
Presenter: Niven Mehra
Session: ePoster Display
643TiP - Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors
Presenter: Hendrik-Tobias Arkenau
Session: ePoster Display